ASBMT Notes Biology of Blood and Marrow Transplantation

Slides:

Advertisements

Similar presentations

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Stephanie J. Lee, Loretta A. Williams

CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic.

How to Treat MDS without Stem Cell Transplantation

Vaccination of Children following Allogeneic Stem Cell Transplantation

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Allogeneic Stem Cell Transplantation in Myelofibrosis

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation Filippo Milano, MD, PhD, Brent.

Sabina Kersting, Leo F. Verdonck

Access to Hematopoietic Cell Transplantation in the United States

Analysis of the Prognostic Effect of Peripheral Blood Lymphocyte and Monocyte Count after Autologous Hematopoietic Stem Cell Transplant in Refractory/Relapsed.

The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation

Let Them Eat! Comparing a Neutropenic Diet to a Food Safety Based Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Cynthia.

Stephanie J. Lee, Loretta A. Williams

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia Hien K. Duong, MD, Mojtaba Akhtari, MD, Kwang Woo Ahn, PhD, Zhen-Huan.

More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors Jo-Anne H. Young, MD, Brent R. Logan,

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Success of an International Learning Healthcare System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation.

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

Pauline A. Daniels, DO, Stella M

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Distinctions Between Effective and Ineffective AML-Specific Autologous Peripheral Blood (PB) Cytotoxic T-Lymphocytes (CTLs) Rohtesh S. Mehta, MD MPH.

John R. Wingard, M. D. , Alan K. Leahigh, Dennis Confer, M. D

Hidekazu Itamura, M. D. , Takero Shindo, M. D. , Ph. D

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Identification of Potential Barriers and Incentives for BMT Nurses to Apply for and Maintain BMTCN Certification Brittney Nicole Browne, BSN, RN, OCN,

Infection Prevention - Visitors and the Best of Intentions

Integrative Therapy Use as a Comfort Measure with BMT Patients

Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.

A Successful Approach to Decreasing Central Line Associated Blood Stream Infections Colleen Butcher, RN, BSN, OCN, Cindy Kramer, RN, BSN, OCN, Carrie.

Myeloid Derived Suppressor Cells (MDSC)-like Acute Myeloid Leukemia (AML) Cells Are Associated with Resistance to Cytotoxic Effects of Autologous (Auto)

The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group Amber B. Clemmons,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pauline Damien, David S. Allan

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

Guidance for Developing Phase II Cell Therapy Trial Proposals for Consideration by the Blood and Marrow Transplant Clinical Trials Network Edwin M. Horwitz,

Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia John Moore, Ian Nivison-Smith,

Gerard Socié, K. Scott Baker, Smita Bhatia

What is quality in a transplant program?

September Mitchell, BSN, MHI, RN, CHTC, OCN, Sarah L

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Blood and Marrow Transplant Handbook

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma Tanya M. Wildes, Kristan M. Augustin, Diane.

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Pure White Cell Aplasia (PWCA) Relapsing after Allogeneic BMT and Successfully Treated with Nine DLIs A.M. Marmont, A. Dominietto, MD, F. Gualandi, MD,

Mammen Chandy Biology of Blood and Marrow Transplantation

Heather A. Himburg, PhD, Liman Zhao, Jenny Kan, John P. Chute, M.D.

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Optimal Donor Selection: Beyond HLA

Donald R. Dengel, Aaron S. Kelly, Lei Zhang, Qi Wang, James S

Radiation Disasters: Role of the BMT Team

Presentation transcript:

ASBMT Notes Biology of Blood and Marrow Transplantation Biology of Blood and Marrow Transplantation Volume 24, Issue 5, Pages 1103-1105 (May 2018) DOI: 10.1016/j.bbmt.2018.03.026 Copyright © 2018 Terms and Conditions

The room was packed for the 7 a. m The room was packed for the 7 a.m. symposium, “Realizing the Promise of CAR T-Cell Therapy for Leukemia and Lymphoma.” Biology of Blood and Marrow Transplantation 2018 24, 1103-1105DOI: (10.1016/j.bbmt.2018.03.026) Copyright © 2018 Terms and Conditions

Over the course of the meeting, more than 700 abstracts were available during oral abstract sessions, peripheral conferences, and poster sessions highlighting the best new research in the field. Biology of Blood and Marrow Transplantation 2018 24, 1103-1105DOI: (10.1016/j.bbmt.2018.03.026) Copyright © 2018 Terms and Conditions

New ASBMT President John DiPersio, MD, PhD (left), honored Immediate Past-President Krishna Komanduri, MD, for his outstanding service. Biology of Blood and Marrow Transplantation 2018 24, 1103-1105DOI: (10.1016/j.bbmt.2018.03.026) Copyright © 2018 Terms and Conditions

Members of the Memorial Sloan Kettering Adult BMT Clinical Research team are all smiles in the Exhibit Hall. Biology of Blood and Marrow Transplantation 2018 24, 1103-1105DOI: (10.1016/j.bbmt.2018.03.026) Copyright © 2018 Terms and Conditions

Rosy Dabas, B.Sc, M.Sc (left) and Kim Hummel, BSN, RN, pose in front of the five Choosing Wisely banners on display at the BMT Tandem Meetings. Biology of Blood and Marrow Transplantation 2018 24, 1103-1105DOI: (10.1016/j.bbmt.2018.03.026) Copyright © 2018 Terms and Conditions

Timothy J. Ley, MD, presented the plenary session, “Genomics and Clonal Evolution of AML” Biology of Blood and Marrow Transplantation 2018 24, 1103-1105DOI: (10.1016/j.bbmt.2018.03.026) Copyright © 2018 Terms and Conditions

Biology of Blood and Marrow Transplantation 2018 24, 1103-1105DOI: (10 Biology of Blood and Marrow Transplantation 2018 24, 1103-1105DOI: (10.1016/j.bbmt.2018.03.026) Copyright © 2018 Terms and Conditions

Biology of Blood and Marrow Transplantation 2018 24, 1103-1105DOI: (10 Biology of Blood and Marrow Transplantation 2018 24, 1103-1105DOI: (10.1016/j.bbmt.2018.03.026) Copyright © 2018 Terms and Conditions